|
KMID : 0921620220520040149
|
|
Journal of Bacteriology and Virology
2022 Volume.52 No. 4 p.149 ~ p.159
|
|
|
In vitro Antiviral Activity of Remdesivir Against SARS-CoV-2 and its Variants
|
|
Nowakowska Aleksandra
Choi Ha-Nul
Park Ki-Hoon
Kim Jin-Ha
Jang Yu-Yeon
Chun Jung-Min
Kim Young-Bong
Lee Hee-Jung
|
|
|
Abstract
|
|
|
|
The outbreak of COVID-19 has become a public health emergency of international concern; thus, it is important to not only develop drugs for treating COVID-19 but also develop a method for evaluating the therapeutic effect based on the characteristics of SARS-CoV-2 and its variants. To test the antiviral activity of a drug against COVID-19, in this study, we established and compared experimental conditions, such as the treatment time and mode of action (dose) of the therapeutic substance, and a test method to evaluate its effectiveness. We optimized an assay for testing antiviral activity by plaque reduction, tissue culture infectious dose 50, and quantitative RT-PCR. These methods were applied to test the antiviral efficacy of the therapeutic against SARS-CoV-2. Antiviral activity testing using in vitro assays against SARS-CoV-2 and its variants was assessed by measuring plaque-reducing or cytopathic effects in Vero-E6 cells. The in vitro assay was validated by evaluating the antiviral activity of remdesivir. Remdesivir reduced SARS-CoV-2 titer without detectable cytotoxicity and successfully inhibited viral replication in a dose-dependent manner. Therefore, we suggest this in vitro assay as an effective method for testing the antiviral activity for a potential repurposed drug against COVID-19 or rapid screening of therapeutic candidates.
|
|
|
KEYWORD
|
|
|
SARS-CoV-2, Variant, Antiviral, Remdesivir, in vitro assay
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|